Physician profile
Mark E Zweben
NPI 1720067077
$2,371.74
in general payments reported to CMS, 2019-2025
26 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $530 · 2021: $96.74 · 2022: $57.82 · 2023: $185 · 2024: $259 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $432.82 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $242.62 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $193.07 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $164.31 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $149.29 | 2019-2022 | |
| Zoll Respicardia, INC. | $134.27 | 2023 | Remede System |
| Pfizer INC. | $125.31 | 2019 | |
| Novo Nordisk INC | $124.39 | 2025 | Ozempic |
| Abbott Laboratories | $121.95 | 2020-2025 | Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.32 | 2019-2020 | |
| Lundbeck LLC | $72.97 | 2019-2020 | |
| Esperion Therapeutics, INC. | $69.57 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $58.96 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.20 | 2019 | |
| Tactile Systems Technology INC | $51.24 | 2019-2024 | Entre Plus, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.39 | 2019-2020 | |
| Amarin Pharma, INC. | $47.66 | 2019-2021 | |
| Boston Scientific Corporation | $37.12 | 2019 | |
| Philips North America LLC | $32.97 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.84 | 2021-2023 | Verquvo |
| Heartflow, INC. | $24.06 | 2023 | Ffrct |
| Hikma Pharmaceuticals USA | $17.80 | 2019 | |
| Akcea Therapeutics, INC. | $17.40 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zweben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.